For more detailed information about the cookies we use, see our Cookies page.
Essential Cookies enable core functionality such as security, network management, and accessibility. These cookies are necessary for the performance of the service and may not be removed.
Non-Essential Cookies are preference, marketing, and functional cookies that help the application perform to its full extent, advertising related to the IdeaScale marketing website, and ensure the application functions properly. Preferences cookies personalize your experience while accessing IdeaScale by remembering your preferences, such as preferred language and region of origin. Analytics cookies collect anonymized information about how you use the IdeaScale services, such as the IdeaScale pages you visit most frequently and the error messages you encounter. These cookies only analyze your movement within IdeaScale and are used to improve the functioning of IdeaScale services. Marketing cookies advertise IdeaScale services to you elsewhere on the Internet. These cookies enable the delivery of interest-based ads that may be relevant to you as a result of your activities on IdeaScale and provide IdeaScale with information (such as where you saw the ad) to help analyze the impact of its advertising campaigns. IdeaScale also includes links to social networks and third-party sites (for example, Facebook and LinkedIn), which may then use information about your visit to target advertising to you on their websites.
What steps can the research community take to facilitate the translation of discovery science into proof of concepts in preclinical models and in humans for diagnosis, prevention, and treatment?
• Current regulatory environment • Lack of communication between discovery and clinical research worlds • Lack of training • Getting industry, academia, and NHLBI to partner; and the business model to make it happen. • Limited...
Is this idea a Compelling Question (CQ) or Critical Challenge (CC)?
Compelling Question (CQ)
Details on the impact of addressing this CQ or CC
• Increased number of novel therapeutics, diagnostics and devices in early phase clinical trials
• Increased impact in rare diseases and unmet needs
• Increased number of licensed IPs from academic centers
Name of idea submitter and other team members who worked on this idea